Reuters logo
BRIEF-U.S. FDA grants designation for HER2-targeting antibody drug conjugate DS-8201
December 1, 2016 / 1:25 PM / a year ago

BRIEF-U.S. FDA grants designation for HER2-targeting antibody drug conjugate DS-8201

Dec 1 (Reuters) - Daiichi Sankyo Co Ltd :

* u.s. Fda grants fast track designation for her2-targeting antibody drug conjugate ds-8201 for her2-positive metastatic breast cancer

* Daiichi sankyo -fda grantd fast track designation to investigational her2-targeting antibody drug conjugate ds-8201 for her2-positive metastatic breast cancer Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below